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Abstract 
No field in health sciences has more interest than organ transplantation in fostering progress 
in RM because the future of no other field more than the future of organ transplantation will 
be forged by progress occurring in RM. In fact, the most urgent needs of modern transplant 
medicine - namely, more organs to satisfy the skyrocketing demand and immunosuppression-
free transplantation -, cannot be met in full with current technologies and are at risk to remain 
elusive goals. Instead, in the past few decades, groundbreaking progress in regenerative 
medicine (RM) is suggesting a different approach to the problem. New, RM-inspired 
technologies among which decellularization, 3D printing and interspecies blastocyst 
complementation, promise organoids manufactured from patients' own cells and bear 
potential to render the use of currently used allografts obsolete. Transplantation, a field that 
has traditionally been immunology-based, is therefore destined to become a RM-based 
discipline.  
However, the contours of RM remain unclear, mainly due to the lack of a universally 
accepted definition, the lack of clarity of its potential modalities of application and the 
unjustified and misleading hype that often follows the reports of clinical application of RM 
technologies. All this generates excessive and unmet expectations and an erroneous 
perception of what RM really is and can offer.  
In this manuscript, we will reason on these aspects of RM and transplant medicine, will 
propose a definition of RM and will illustrate the state of the art of the most promising RM-
based technologies of transplant interest. 
  
Introduction 
Regenerative medicine (RM) has shown an immense potential to profoundly impact 
transplant medicine (TM) by meeting its two most urgent needs: a new and potentially 
inexhaustible source of organs and the achievement of an immunosuppression-free status[1].  
Through the development of technologies that will make organ fabrication possible using 
patient-derived biomaterials – cells and supporting scaffolding materials – RM promises to 
enable organ-on-demand whereby patients will receive organs that will not be rejected and in 
a timely fashion. This will make registration in the waiting list and anti-rejection medications 
unnecessary and, as the new organs will be implanted immediately after fabrication, 
ischemia-reperfusion injury secondary to organ preservation will not be a problem anymore. 
However, the contours of RM remain unclear, mainly due to the lack of a universally 
accepted definition, the lack of clarity of its potential modalities of application and the 
unjustified and misleading hype that often follows the reports of clinical application of RM 
technologies. All this generates excessive (and unmet) expectations and an erroneous 
perception of what RM really is and can offer. 
With the present manuscript, we intend to address these concerns, propose a definition of RM 
pertinent to TM and elucidate the RM technologies that may be applied to and serve the 
mission of TM. We will also briefly discuss the most relevant product development 
challenges and the immunological implications of the biomaterials currently under 
development.  
 
Definition 
“Regenerative medicine” is an umbrella term of still unclear significance. For example: in 2006 the 
United Nations Educational, Scientific and Cultural Organization (UNESCO) defined RM as a super-
discipline whose contours are still being defined 
(http://unesdoc.unesco.org/images/0014/001454/145409e.pdf). In the document, it was stated that the 
definition of RM “can be either narrow or very wide” and that the field “is generally about 
replacement, repair and regeneration to address deficient organ function resulting from congenital 
defects, disease, trauma or wear and tear”. From this definition, it may be inferred that RM and TM 
share the same interests and pursue the same goal, namely the replacement of terminally diseased 
organs with new functioning organs. However, while the term replacement is intimate to organ 
transplantation, repair and regeneration are not, unless we consider the case of auxiliary heterotopic 
liver transplantation, performed to allow the native liver devastated by an acute damage to regenerate 
and resume normal function[2].  
More recently, the term RM has been used to define – more succinctly – a field in the health sciences 
that aims to replace or regenerate human cells, tissues, or organs to restore or establish normal 
function[3]. The process of regenerating body parts can occur in vivo or ex vivo and may require cells, 
natural or artificial scaffolding materials, growth factors, gene manipulation, or combinations of all 
the four elements. However, RM is commonly used as synonymous to “tissue engineering”, but it has 
been noted that “tissue engineering” is “narrower in scope and strictly defined as manufacturing body 
parts ex vivo, by seeding cells on or into a supporting scaffold”[4]. According to NIH, “tissue 
engineering evolved from the field of biomaterials development and refers to the practice of 
combining scaffolds, cells, and biologically active molecules into functional tissues”, with the 
ultimate goal of assembling “functional constructs that restore, maintain, or improve damaged tissues 
or whole organs” (https://www.nibib.nih.gov/science-education/science-topics/tissue-engineering-
and-regenerative-medicine ). 
The NIH also defines RM as “the process of creating living, functional tissues to repair or replace 
tissue or organ function lost due to age, disease, damage, or congenital defects. This field holds the 
promise of regenerating damaged tissues and organs in the body by stimulating previously 
irreparable organs to heal themselves; […] empowers scientists to grow tissues and organs in the 
laboratory and safely implant them when the body cannot heal itself. Importantly, regenerative 
medicine has the potential to solve the problem of the shortage of organs available through donation 
compared to the number of patients that require life-saving organ transplantation”. 
(https://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=62). This definition is quite 
comprehensive but neglects two critical aspects of modern TM, namely immunosuppression-free 
transplantation and ischemia-reperfusion damage deriving from organ preservation and storage. In 
fact, RM research aims at building autologous tissues and organs from patient’s own cells with the 
ultimate goal of bypassing the need for lifelong anti-rejection therapy, with consequent obvious 
clinical and financial benefits. Moreover, by enabling physicians to implant bioengineered organs 
immediately after maturation, ischemia-reperfusion damage is prevented. 
Last, to the best of our knowledge, none of the societies that may claim parenthood to the field of RM 
has ever released an official definition of the term.  Therefore, we herein propose the following 
definition: 
 
RM is a field in the health sciences that aims to regenerate, repair or replace functionally 
impaired tissues and organs in order to restore normal function. The process of regenerating body 
parts can occur in vivo or ex vivo and may require cells, natural or artificial scaffolding materials, 
growth factors, genetic manipulation, or combinations of them. RM promises to address the longest 
standing limitations of organ transplantation, namely the identification of an inexhaustible source of 
transplantable organs, immunosuppression-free transplantation and organ-on-demand, whereby a 
patient in need and deemed suitable for transplantation is enabled to promptly receive an organ that 
will be bioengineered from his/her own cells. This will rule out the need for lifelong 
immunosuppression and, by allowing implantation of the graft immediately after production, will 
likely prevent the damage resulting from organ preservation, storage and ischemia-reperfusion. As a 
corollary, RM will eliminate the waiting list. 
 
 
RM technologies applied to organ transplantation  
Decellularization.  The term decellularization refers to a process whereby the cellular compartment 
of living tissues is removed by chemical or physical means[5]. The end product of this process is an 
acellular scaffold consisting of the innate extracellular matrix (ECM) of the original tissue that is 
being used for different purposes. For example, acellular scaffolds may serve as template for the ex 
vivo bioengineering of implantable organs[6], or to promote functional tissue restoration after 
implantation in vivo[7]. In the first case, the scaffold will be recellularized with progenitor or adult 
cells first, and either allowed to mature in bioreactors before implantation or implanted directly in 
patients thereafter [8]. In the second case, the acellular scaffold is implanted in the diseased tissue to 
orchestrate a constructive remodeling in situ[7].  The rationale behind these applications is that the 
ECM is the fundamental 3D network that not only provides structural support to cells, but by 
interacting with cell surface molecules and serving as a reservoir for growth factors, also plays a 
critical role in tissue and organ development, homeostasis and regeneration after damage[9]. Although 
the decellularization process does produce some damage to the innate ECM, the scaffolds produced 
with current technology retain most of the biochemical complexity, nanostructure, and bioinductive 
properties of the native matrix that are essential for cells to attach, migrate, proliferate and function, 
and have been shown to promote the creation of site-specific, functional tissue in vivo[10]. Moreover, 
as the framework of the innate vasculature is preserved, patent, and able to sustain the physiological 
blood pressure[11], acellular ECM scaffolds (aECMs) seem ideal for the bioengineering of 
transplantable organs. AECMs may also be a source of hydrogel and used as such as cell delivery 
tool.  Notably, more than 80 ECM based products are currently available in the market for a variety of 
clinical applications[12]. 
From a TM perspective, the use of aECMs as a template for whole organ bioengineering undoubtedly 
holds immense potential. Since the milestone report on the bioengineering of a functional heart in 
2008[13], more than two hundreds papers have proven that aECMs may be produced from virtually 
all transplantable organs from clinically relevant animal [11, 14-16] and human donors [16-24], 
including the human hand, face and face subunits [25-29]. As one of the major objectives of RM is to 
identify an inexhaustible source of organs, animals may be considered an ideal source of aECMs for 
intra-abdominal and intra-thoracic bioengineering, whereas human donors should provide organs for 
limb, face and face subunit bioengineering for obvious reasons. Interestingly, the term semi-
xenotransplantation has been proposed to indicate the bioengineering of implantable organs whereby 
aECMs of animal origin are seeded with human cells [30]. 
Despite the fact that viable and functioning bioengineered tissues and/or organs supplied with their 
own vascular pedicle have never previously been described in animal models, the literature reports a 
few anecdotal cases [8, 24, 31-34] or small studies in humans [35]  where  relatively complex tissues 
were transplanted without any vascular pedicle, and therefore lacked an immediate connection to the 
recipient’s vasculature. Although some short-term success has been obtained, and to some extent, it 
can be claimed that the proof of concept has been provided, the reported morbidity and mortality are 
extremely high [36]. This probably reflects our incomplete understanding of the biology of organ 
regeneration and underestimation of the true anatomical and physiological complexity of the organs in 
question[37]. As recently stigmatized by Badylak in an illuminating editorial, the big mistake that has 
been reiterated by tissue engineers in the past decade is the erroneous belief that organs can be 
manufactured without the critical elements required to maintain the viability and function of all living 
tissues; namely, adequate lymphatic and innervation networks, and – more importantly –  
vascularization [38]. Moreover, most clinical and experimental studies report that after cells are 
seeded on aECMs, the so-obtained construct is allowed to mature in bioreactors for conventional 
periods of one or few weeks, which is probably insufficient as this is much shorter than the time 
needed for any given organ to develop in utero. 
 
3D printing technology.  3D bioprinting promises to have a disruptive impact in TM and represents a 
significant technological advancement in the manufacturing processes used for tissue and organ 
engineering. Where the conventional manufacturing approach requires the manual fabrication by a 
skilled technician, 3D bioprinting is automating this process, with subsequent improvements in 
standardization, reproducibility, resolution and accuracy. These advances have arisen from the 
adoption of design and manufacturing techniques used in the non-biological manufacturing sector, 
such as the use of imaging and design software, and the increased availability, and reduced cost of 3D 
printing hardware. 3D printed medical devices have already been transplanted into patients [39, 40], 
and simple bioprinted tissues such as cartilage and bone have been successfully transplanted in 
preclinical animal studies [41-43]. However, just like above, current 3D bioprinted tissues lack 
essential functional elements such as vasculature, innervation, lymphatics and the number and 
diversity of functional and supporting cell types required for more complex or larger tissues and 
organs.  
In health care, 3D printing has been applied for the manufacturing of surgical guides, anatomical 
models and prosthetics [39], and more recently, for custom implants [44]. Medical uses of 3D printing 
have usually been confined to static, non-living constructs, including patient-specific craniofacial 
implants and hip and mandibular prostheses [40]. In 2013, the clinical application of 3D printing was 
expanded, with the implantation of a 3D printed, bioresorbable external airway splint into an infant 
with tracheobronchomalacia, which was followed up with a 2015 report of a further 3 infants recei 
ving patient-matched 3D printed splints [45]. These constructs, while non-living, were designed 
to prevent external airway compression over a predetermined time period before bioresorption to 
accommodate airway growth [46]. While these advances have demonstrated the promise of 3D 
printing technology for medical applications, the progression from non-living constructs to 3D printed 
living cellular constructs has not been as rapid. Significant challenges surrounding the formation of 
complex, heterogeneous tissues, with sufficient vasculature, innervation, and function, means that we 
are currently years away before even simple constructs make their way into clinical use. It is likely 
that the first advances in the clinical transplantation of 3D printed living tissues will be made in 
relatively simple tissues before advancing to tissues with more complex geometries, cell types and 
functions. 
In contrast to many other tissues, cartilaginous tissues are avascular and aneural structures 
containing a relatively low density of cells, potentially minimizing three of the most difficult hurdles 
in the field. For this reason, cartilaginous tissues are likely to be one of the first types of 3D printed 
tissues to progress to clinical transplantation, and multiple examples of 3D printed cartilage tissue 
have been described at the pre-clinical stage of development. Cui and colleagues have applied inkjet 
3D printing technology to repair human articular cartilage [41], achieving a tissue construct with a 
compressive modulus in the same order of magnitude as hyaline cartilage [47].  
Another novel approach involves the fabrication of tissue constructs using self-assembling 
spheroids of chondrocytes to form cartilage strands, significantly increasing cellular density and 
improving post-transplantation maturation and function [48]. Recently, the biofabrication and 
implantation of human-sized 3D printed cartilage tissues has been reported, with tissue constructs 
possessing histological and mechanical characteristics of human auricles after animal implantation in 
vivo [49]. 
Bone has been well studied by the materials engineering community due to its unique structure 
and mechanical properties. Biomaterial scaffolds that exploit the inherent properties of nanoparticles 
have been developed that meet the physicomechanical requirements of bone regeneration, formulated 
to control the mechanical properties and degradability of scaffolds upon transplantation [50]. In one 
example, Inzana and coworkers fabricated a calcium phosphate, collagen composite bone scaffold 
using a modified inkjet-based 3D printer. The implants were confirmed to be osteoconductive and 
biodegradable in a critical sized murine femoral defect [43]. However, to date, many 3D printing 
approaches rely only on hard scaffolds to reproduce the appropriate mechanical properties for cortical 
bone, but fail to fully recapitulate the cellular, spongy component of cancellous bone. One approach 
to overcome this limitation includes incorporating bone marrow-derived mesenchymal stromal cells 
into osteoconductive hydrogel bioinks. These soft bioinks are then supported by a network of 
reinforcing poly(ε-caprolactone) (PCL) microfibers to enable the fabrication of mechanically 
reinforced constructs with decoupled biological and mechanical functionality. These 3D printed 
constructs mimic the geometry and bulk mechanical properties of trabecular-like endochondral bone 
with a supporting marrow structure, and undergo endochondral ossification over time following 
implantation [51]. Using a similar approach, human-scale mandible and calvarial structures have been 
3D printed, with size and shape similar to what would be needed for facial reconstruction after 
traumatic injury. Implantation of 3D printed bone constructs into animal defect models resulted in the 
formation of mature, vascularized bone tissue in implants retrieved up to 5 months later [49]. 
The application of 3D printing technology to fabricate relatively simple tissues such as cartilage 
and bone has been facilitated by the development of new biomaterials and 3D printing technology that 
can accurately and reproducibly deposit these materials. 3D bioprinting techniques can be broadly 
classified by their mechanism of cell deposition into inkjet [52], microextrusion [49, 53-55], or laser-
assisted bioprinting [56-58]. The basic technologies and their applications have been extensively 
reviewed [59, 60]. Recent advances in bioprinter technology have facilitated the patterning of multi-
component constructs containing both synthetic and natural materials capable of resolution down to 
2µm for biomaterials alone and down to 50 µm for encapsulated cells [49]. Further progress in the 
field will require the ability to deposit an even wider range of material types concurrently with 
increases in print resolution and speed. Some progress has been made in this area, such as the use of 
microfluidic switching nozzles that swap between two different inks on demand [61], as well as 
mixing nozzles that can be used to print materials at the microscale with tunable gradients of differing 
material properties [62]. Additionally there has been remarkable achievements in the high-resolution 
patterning of matrix materials using light-based free-form fabrication. One example of this is two-
photon lithography, where transparent photoresist materials are photopolymerized with multiphoton 
absorption events with highly controllable focal volumes and print speed [63]. 
The combination of materials that provide mechanical strength and those that are compatible with 
cell function has resulted in the successful fabrication of human scale, cellular tissues that have shown 
long-term function post-transplantation. Biomaterials commonly used for bioprinting are 
predominantly based on either naturally derived polymers (such as tissue-based extracellular matrix 
proteins including alginate, gelatin, collagen, chitosan, fibrin and hyaluronic acid) or synthetic 
molecules (polyethylene glycol; PEG). Often, the synthetic materials provide physical integrity at the 
at the macro level, while softer materials, such as hydrogels, provide an appropriate environment for 
cell encapsulation and placement. However, synthetic materials often fail to provide physiological 
interactions with the cellular component. On the other hand, the weak mechanical properties of 
hydrogels is a considerable limitation for their contribution to the physical properties of the tissue. 
Further advances in the development of biological materials are needed to improve control of the 
structural, mechanical, and biological properties of constructs to replicate tissue structure and function 
[64, 65]. One approach towards overcoming this challenge include chemical modification of the 
hydrogels to enable the materials to cross-link with other materials, therefore controlling its 
mechanical strength or other parameters such as degradation times. Synthetic hydrogels like PEG-
based hydrogels have been modified to covalently tether ECM-derived biomolecules [66]. Similarly, 
there is a need for the continued development of 3D printers that are specifically designed for these 
biological materials, combined with the decreased cost of these technologies. 
However, before we can expect to see successful 3D printing of larger, or more complex tissue 
types, several significant limitations and obstacles need to be overcome. For larger tissues, the 
incorporation of intact vasculature will be essential for the survival and function of the implanted 
tissues. One potential approach to overcome this bottleneck is the utilization of light-based 3D 
printing technology, capable of photopolymerizing a wide range of biological materials, with 
significantly improved speed and resolution. For example, microscale continuous optical bioprinting 
(µCOB) has been used to create prevascularized tissue constructs within a soft hydrogel network [67]. 
The ability to pattern increasingly complex cellular structures with increased resolution would provide 
many opportunities to incorporate other functional tissue components and architectures such as 
vascular, neural and lymphatic networks and potentially lumens, tubules and ducts. Another limitation 
to the fabrication of larger, more complex tissues is the requirement for increased quantity and 
diversity of cell types. Many studies have utilized either primary cells or tissue-derived multipotent 
stem cells, but the limited expansion and differentiation capacity of these cell types may limit their 
application for larger or more complex tissues. Potential approaches to overcome this problem include 
involve viral transfection [68] or use of small molecules to induce cell proliferation or differentiation 
[69, 70]. 
 
Stem cell technology.  Cells within the inner cell mass of blastocyst-stage embryos give rise to all 
adult cell types and are thus termed ‘pluripotent’. In 1981, it was discovered that these ‘embryonic 
stem cells’ (ESC) could be isolated from mouse embryos and expanded in culture without losing their 
pluripotency [71].  Following the isolation of the first human ESC lines in 1998 [72], there was huge 
optimism that these cells could not only replace cells lost in degenerative diseases such as Parkinson’s 
disease, but could also be combined with natural or bioengineered scaffolds to generate replacement 
tissues and organs [73].  However, apart from the ethical issues surrounding the use of human 
embryos, several challenges facing the development and application of ESC-based therapies were 
soon identified, including (i) their tumorigenic risk; (ii) the need for reliable culture conditions to 
direct their differentiation to fully functional specialized cells; (iii) strategies to prevent immune-
rejection.  
Much progress has been made; for instance,  methods to identify and remove undifferentiated 
ESCs from administered cell populations have now been developed [74],  reducing the risk of  tumor 
formation; and although some ESC derivatives  remain functionally immature [75, 76], others, such as 
ESC-derived retinal pigment epithelial cells, display the typical characteristics of their adult 
counterparts [77] and have already been applied in clinical trials [78]. Some ESC-based therapies can 
involve the transplantation of progenitor cells which then further differentiate in vivo to generate 
functionally mature cell types; for example, ESC-derived dopaminergic neuron progenitors can 
undergo maturation in rats with chemically-induced Parkinson’s disease and can ameliorate motor 
deficits [79]. The problems with immune-rejection, however, still remain, because ESC are non-
autologous. Therefore, unless ESC-based therapies are applied to immune-privileged sites like the 
retina and brain, immune-suppressant therapies or other strategies to prevent immune-rejection are 
required.  
Reports that pluripotent stem cells could be isolated from bone marrow[80] appeared to 
circumvent the aforementioned ethical issues as well as the problems with immune-rejection, as these 
cells can be self-derived. Although it is now clear that the bone marrow does not harbor pluripotent 
stem cells, there is good evidence that multipotent mesenchymal stromal cells (MSC) isolated from 
various sources, including bone marrow, adipose tissue and umbilical cord, have the potential to 
generate bone-, cartilage- and adipocyte-like cells following in vitro culture under specific conditions 
[81]. This has led to much enthusiasm regarding the use of autologous MSC-derived cells in 
combination with biomaterial scaffolds to generate replacement tissues for transplantation, an 
example being the use of MSC-derived chondrocytes to regenerate cartilage in the upper airway [24]. 
However, although such constructs have been used in human patients under ‘compassionate use’, data 
from animal studies indicate that MSC-derived chondrocytes fail to engraft and there is no evidence 
of cartilage regeneration [82], which might partly explain the high mortality rates observed in the 
clinic [83]. Most studies now show that while MSC and other somatic cell-based regenerative 
medicine therapies can have significant beneficial effects, these are mediated by paracrine factors that 
either directly or indirectly stimulate endogenous repair [84-86]. Thus, while MSC could be useful for 
promoting the repair and regeneration of transplanted tissues and organs, it is unlikely that they will 
be able to directly replace damaged tissues [87]. For instance, liver MSC-derived exosomes 
administered in an ex vivo normothermic liver perfusion system displayed regenerative functions and 
promoted in vivo repair [88].  
The seminal work of Yamanaka, who showed that somatic cells could be reprogrammed to 
generate induced pluripotent stem cells (iPSC) that have the same plasticity as ESC [89, 90], 
addressed some of the problems encountered with ESC and MSC; for instance, iPSC generation does 
not require human embryos, they can be patient-derived, and unlike MSC, they are pluripotent. The 
plasticity of iPSC raises the possibility that they could be used as a source of specialized cells types 
for the recellularization of tissue and organ scaffolds for transplantation. Indeed, iPSC appear to 
represent a potentially unlimited supply of pluripotent cells that could overcome cellular challenges 
related to quantity and specificity of cell sources for recellularization [91]. Improvement in 
pluripotent stem cell differentiation techniques are continuously in development [92]. Further 
optimization has to be determined exploiting the local cues and the functional stimuli occurring in the 
in vivo setting to acquire functional maturation. While some progress has been made with de- and 
recellularization of kidney [93], heart [21], pancreas [94] and liver scaffolds [95], at present an 
adequate kidney scaffold recellularization in vivo appears challenging and available infusion protocols 
inadequate [96].   
Overall, several additional key points need to be clarified to make stem cell research more 
realistic and practical. The extent and quality of vascularization required by tissue-engineered 
constructs for their in vivo stabilization and maintenance still need to be determined [97]. RM would 
benefit of methods to allow a constant in vivo tracking of cell viability and functions. Magnetic 
resonance imaging and optical imaging appear the more suitable approaches for high spatial 
resolution and high sensitivity, respectively. A fist approach to track endothelial after seeding in a 
trachea scaffold has been recently reported using bioluminescence technology cells [98]. 
 
Organoids and blastocyst complementation. Apart from the potential of using iPSC in combination 
with scaffolds for tissue replacement, recent progress has been made towards generating 3-
dimensional iPSC-derived organoids in vitro representative of several different organ systems, 
including renal, liver and heart organoids [99]. Exciting breakthroughs have been made with renal 
organoid development in particular, where it has been shown that iPSC-derived renal progenitor cells 
can generate organoids comprising all key renal cell types [100]. While organoids could potentially 
open the door to the development of bioengineered tissues and organs for transplantation in the future, 
many problems first need to be overcome, including appropriate vascularization. This is actually a 
major challenge because in the developing embryo, the major organ systems develop together with 
their capillary network and main feed arteries, ensuring that blood is supplied at the correct pressure. 
This problem is exemplified by a previous study showing that fetal rat kidneys do not mature beyond 
a neonatal stage following transplantation into adult rats, likely due to their abnormal vasculature and 
failure to develop a renal artery [101]. 
A potentially more promising iPSC-based technology for generating autologous tissues and 
organs for transplantation is interspecies blastocyst complementation (IBC). In this approach, genetic 
manipulation of the host precludes the development of an organ which is then compensated by stem 
cells from a donor that produce the missing organ. Proof of principle for this approach was 
demonstrated in 1993 to generate T and B lymphocyte lineages by implanting murine ESC into the 
blastocysts of  Rag2−/− mice [102]. Using host blastocysts derived from Pdx1-/- mice that display 
pancreatic agenesis, Melton’s group showed that complementation with wild-type mouse ESCs 
resulted in the pancreatic epithelium being derived from the donor Pdx1+/+ cells [103].  A later study 
showed that complementation of Pdx1-/- mouse blastocysts with rat iPSC resulted in the development 
of functional rat pancreases within the adult mice hosts, thus demonstrating interspecies 
complementation [104]. These groundbreaking studies raise the possibility that, by genetically 
modifying pig blastocysts so that they are unable to generate specific organs, and then complementing 
with patient-derived human iPSC, it could be possible to generate autologous organs for 
transplantation within the host pig. A key advantage of this approach is that apart from being 
autologous, functional and of the correct size, the organs could be transplanted with their own 
vascular pedicle. However, a number of challenges need to be addressed. For instance, although rat 
iPSC could generate pancreata within mouse hosts, they were unable to generate kidneys in Sal1-/- 
mice that display renal agenesis [105], suggesting that for some organs, additional modification of the 
donor iPSC might be required to enable them to interact appropriately with the developing host 
embryo. Furthermore, previous attempts to undertake interspecies complementation using human 
pluripotent stem cells and mouse blastocysts have had limited success [106, 107]. Nevertheless, using 
a ‘primed’ pluripotent state, Belmonte’s group has shown that human pluripotent stem cells could 
contribute to developing mouse embryos following grafting into gastrulating mouse embryos [108], 
thus providing proof of principle for interspecies blastocyst complementation using human iPSC. 
Importantly, while decellularization and 3D printing rely on bioreactors for the maturation of the 
bioengineered constructs, with this technology, the organs develop in utero, which presents the most 
convenient and physiologically appropriate conditions.  
However, some issues related to the generation of interspecies blastocyst complementation 
derived organs need to be faced. The purity of the generated organs, in terms of cell composition, 
need to be addressed. In fact, endothelial cells or other cell types derived from the host could 
contaminate the donor-derived organ. In addition to the technical problems, ethical concerns has been 
emphasized in relation to the possibility that human cells could contribution to the formation of non-
targeted organs, such as brain or germ cells, generating chimeric brains or fetuses [109]. 
 
Expanding the donor pool by the application of regenerative medicine strategies.  The narrowest 
concept of RM presumes the creation of neotissues from a cell source.  This presumptive approach 
entails addressing barriers that may take decades to overcome including those related to 
manufacturing practicality, safety, regulation and cost/reimbursement. However, established solid 
organ transplantation may be considered to already encompass a truly RM approach best illustrated by 
the successful transplantation of kidneys with severe acute kidney injury and most recently, donation 
after circulatory death (DCD) heart transplants. These clinical successes have allowed organs 
historically considered unusable to be successfully transplanted but the approach in each case relies 
on firstly predictable in-vivo regeneration but in the latter case, actively managed ex-vivo muscle cell 
regeneration in the context of normothermic reperfusion. 
Given the exceptionally successful results of solid organ transplants and the global “mantra” 
that this excellent selection of treatments is limited only by organ availability, it is possible to reason 
that managed regenerative treatment of the many thousands of deceased donor organs currently 
declined for transplant worldwide may represent a rapid route for clinical translation of the variety of 
regenerative therapies currently being developed. This diverges from the assumption that the 
generation of functioning neotissue is essential for patient benefit and instead uses regenerative cells 
or alternative therapies to protect the intrinsic regenerative capability of the solid organs from damage 
and promote its augmented activation, during and after the multifaceted phase of peri-transplant graft 
injury. 
This indication is evidently a major arena of clinical need. Candidate regenerative 
interventions – with the potential for multiple mechanisms of action – may be more effective and are 
already in phase 1 studies with particular promise for the application of MSC or pleomorphic 
regenerative cell populations such as those derived from adipose tissue.  The former have been widely 
administered for immunoregulatory purposes but increasingly the focus of such therapies is more 
regenerative with a recent study in ex-vivo perfused human livers confirming up to 50 x 106 cells can 
be delivered safely via the hepatic artery.  The latter have been safely administered intra-arterially or 
intra-portally, without vascular complications in animal models of kidney [110], lung and liver as well 
as directly into porcine and human coronary arteries [111-113]. These interventions have the added 
advantage of ex-vivo applicability in the context of organ storage or normothermic machine 
perfusion.  This latter scenario offers the opportunity for regenerative therapy in the context of 
optimized biodistribution and pre-implantation efficacy/safety assessment. 
An alternative RM-based approach may be molecule-based, in spite of the fact that multiple 
small molecule approaches for the indication that we are herein discussing have already failed to 
show clinical benefit. While on one hand this failure is likely to reflect the extensive redundancy in 
mechanisms of peri-transplant injury, on the other hand failure may simply tell us that we have not 
picked the right drug(s)! Ideally, we should consider molecules possessing high regenerative potential 
rather than molecules that target this or that pathway of the inflammatory response complicating 
ischemia-reperfusion. For instance, recent groundbreaking work from MDI Biological Laboratories 
identified MSI-1436 as a first-in-class regenerative medicine drug candidate [114]. In fact, in adult 
zebrafish, administration of MSI-1436 stimulated the rate of regeneration of caudal fin tissue and 
heart muscle by 2–3-fold without apparent tissue overgrowth or malformation. Moreover, 
administration of the drug to adult mice for 4 weeks beginning 24 h after inducing cardiac ischemia 
increased survival, improved heart function, reduced infarct size, reduced ventricular wall thinning 
and increased cellular proliferation in the infarct border zone. In a Phase 1 and 1b clinical trials 
attesting the potential of MSI-1436 for treating obesity and diabetes, good tolerability was 
demonstrated, and it was found that doses effective at stimulating regeneration were 5–50-times lower 
than the maximum well tolerated human dose; hence, this molecule shows great promise for 
applications in multiple TM scenarios. 
Given the major financial effects associated with delayed graft function of solid organ 
transplants, regenerative therapies in this context may also find a role in reducing peri-transplant 
injury and augmenting post implantation regeneration even in those solid organs currently utilized for 
transplant. 
 
 Product development challenges for cell-based therapies  
a. Scaling-up production. The scaling up of cell production is not a trivial process as the physical 
environment where the bioengineered tissue will be implanted will exert a number of known and 
unknown effects on the physiologic and phenotypic characteristic of the final product. The type, 
dimension and material where cells are grown is known to impact their characteristic including cell 
proliferation rate and differentiation potential. Using standardized modular unit in parallel is usually 
the simplest and safest approach to scaling up from laboratory to industrial production for products 
dedicated to single individuals. However, this approach result also in an increase of cost, labor and 
risk of failure for single units (http://www.bioprocessintl.com/manufacturing/cell-
therapies/streamlining-cell-therapy-manufacture-328083/).   
As illustrated above, the integration in a tridimensional structure of different cell types can be 
obtained using ECM as an instructing guide. However, the timing, composition and degree of 
differentiation of the cell populations used to regenerate the cellular compartment of these structure 
remains unclear, as well as the stimuli needed to obtain a complete differentiation before (or after) 
implantation.  Due to the complexity of the function of complex modular organs like the kidney or the 
heart [115], the issue of scaling out is depending on the ability to replicate the essential manufacturing 
characteristics in different physical location and/or time.  This in turns depends on the ability to 
identify the key factors regulating the consistency of the manufacturing process and control them 
[116](https://nam.edu/manufacturing-cell-therapies-the-paradigm-shift-in-health-care-of-this-
century/). Single use modular apparatus are likely to be the simplest answer to this particular need.  
Assessing a complex construct requires the understanding of the specific characteristic 
desired for any given clinical application and the technologies to measure them. Both non-invasive 
approaches and surrogate biomarkers will have to be developed in order to perform the identity 
qualification of the final product, both in terms of functionality and expected half-life after 
transplantation.  However, while it is possible to standardize production, it may be difficult to apply 
the principle of "one-size-fits-all" to the recipient due to the intrinsic inter-individual variability but 
also to environmental effects. Adaptation of the process to a finite number of possible recipients is 
likely to be a necessary step. 
  
b. Key attributes of proposed RM interventions/products that demonstrate their readiness to be 
advanced into clinical trials.  
1) Critical quality attributes 
In order to progress to application in humans, any new RM product should have a clear indication in 
terms of expected functions in vivo, the definition of surrogate biomarkers for the estimation of the 
efficacy and an imaging technology to assess the integration and biodistribution. The expected half-
life in vivo should be clear, and remedial approaches in case of failure should be well defined. The 
choice of parameters defining the products (i.e. identity) should be justified by a risk assessment and 
the intended use 
(https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformati
on/Guidances/CellularandGeneTherapy/ucm081670.pdf and 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC5000039
87.pdf). 
  
2) Critical process parameters  
The critical process parameters are strictly depending on the cell type and need to cover basic safety 
and efficacy in vivo after transplantation. Both donor and recipient characteristics should be included 
in the evaluation of these parameters. Usually these parameters encompass at least cell number, 
viability and proliferative index, which per se do not exclude the necessity of more specific biomarker 
testing.  
  
3) Material attributes 
As the cells respond in a complex – yet, still not fully understood – manner to the materials present in 
the culture media and containers used during the manufacturing process, any substitution or alteration 
has to be carefully assessed against the panel of final desired characteristics. Depending on their 
complexity, such assurance could be obtained by either testing the materials before accepting them for 
the manufacturing process, or by the full qualification of the supply chain. A strict definition of the 
materials sourcing should be established early in the development process.  
  
c. What are the key regulatory science questions that should be addressed in the next five years? 
The understanding of the expansion limit of the different stem cell lines with potential for clinical 
applications is the first knowledge gap to be filled. Stem cells should be expanded and harvested 
without incurring in genomic alterations that would obviously undermine safety. Such limit is now 
defined in a conservative way for MSC [117] but remains unclear for ESC and iPS.  However, the 
necessity to obtain and qualify new donor cell population regularly constitute a strong limitation to 
the application on a large scale of RM.  
Information about the stability of the transplanted organ/tissue and its response to 
environmental stimuli in vivo is fundamental for progress in the field but will be obtained only after a 
more substantial number of applications will be done. Currently, it is not possible to predict the fate of 
an artificial tissue in vivo, which could engraft permanently while exerting (some) function, but may 
also fail in time, or be colonized and replaced by endogenous cell. The long-term stability and the 
ability to exert (to some extent) physiological function(s) after implantation will therefore have to be 
determined.  In this scenario, it will be critical for authors to disclose with honesty and integrity not 
only short- or mid-term results, but also the long-term results. On their side, journals should require 
authors to provide outcome updates on a regular basis. 
As discussed above, so far it has been common practice to implant bioengineered tissues 
without the reconnection to the blood stream of the recipient or the nervous system. For solid organs 
or vascularized composite allografts, this is not an option. Therefore, research should devise strategies 
to allow the integration of the vascular and nervous system of the host with the bioengineered tissue.  
 
 
Regenerative immunology 
One of the most critical questions to answer is how the immune system could react against a 
bioengineered cellular construct and if it would be possible to modulate this response [118]. A 
bioengineered construct consists of two components, the cellular compartment and the cell-supporting 
system, namely the ECM. While a fully developed lab-grown organ consisting in well differentiated 
cells deriving from a genetically different donor will certainly be subjected to the same well codified 
immune response as an allograft, it was initially speculated that tissues derived from allogeneic 
pluripotent stem cells (PSCs)- were not immunogenic and could therefore evade allorecognition 
[119]. This hypothesis was based on the observation that primordial cells like PSC present low MHC 
expression and immunogenicity, and that lab-engineered biological constructs lack dendritic cells and 
a lymphatic system that are primary drivers of alloimmune response. However, a growing body of 
literature has clearly shown that PSC are not immune privileged and that even tissues derived from 
autologous iPS may elicit an inflammatory reaction and succumb to rejection [119]. Therefore, 
strategies to promote local or systemic tolerance or immunomodulation are currently under 
investigations. One approach to solve the problem of graft immunogenicity is the cloaking of lab-
grown (allo- or auto-) grafts in immune-neutral substances, such as nanofilms [120-123]. 
Alternatively, researchers are assessing whether the constitutive secretion of immune-modulating 
cytokines, including TGF-beta, by tissues differentiated from PSC promotes polarization of 
infiltrating T cells toward a regulatory T cell (Treg), immune modulatory phenotype [119, 124-126]. 
Interestingly enough, natural ECM-based scaffolds obtained from human organs that are being used 
as supporting scaffolding material for bioengineered tissues, have been reported to contain significant 
amount of TGF-beta [127-130] and to be able to induce T-cell apoptosis and promote conversion of 
naïve CD4+ T cells into CD4+CD25+Foxp3+ Treg [118, 129]. This observation is consistent with the 
evidence showing that the ECM possesses strong immunomodulatory properties. Studies in rats 
showed that rabbit acellular decellularized muscle scaffolds down-regulated T cell xenogeneic 
responses and TH1 effector function compared to fresh tissue  by inducing a state of peripheral T cell 
hyporesponsiveness [131].  Moreover, ECM obtained from human normal or diseased organs, 
promote a protolerogenic macrophage polarization similar to the one that is observed in the adaptive 
regenerative healing response whereby a phenotypic transition from the pro-inflammatory M1 to the 
immune-modulating M2 phenotype occurs [128, 132, 133].  Therefore, combining the intrinsic ability 
of PSC-differentiated tissue to release TGF-beta with the immunomodulatory properties of ECM-
based scaffolds, may represent a valuable strategy to reduce immunogenicity of bioengeneered 
organs.   
 
 
Conclusions 
The transplant era began in 1902 in Vienna, with the successful autotransplantation of a 
kidney in the neck of a dog performed by Hungary born surgeon Emerich Ullman who however did 
not succeed in performing any transplant in humans. It took fifty-two years before the first successful 
renal transplant could be executed in humans, and more than seven decades before transplantation 
became standard of care for a myriad of clinical settings requiring replacement surgery. In the past 
few decades, a new field of health science referred to as RM has shown potential to deliver to the 
bedside organs manufactured from patient’s own cells thus bypassing allorecognition and ultimately 
rendering anti-rejection medication unnecessary. In doing so, RM promises to meet the more urgent 
needs of our field, proposes a new Holy Grail for modern TM[1] and identifies a field of investigation 
of immense interest to transplantation (Figure 1). 
Few patients have truly benefited from the successful implantation of bioengineered organs, 
while in the majority of others the graft did not work. Moreover, the anatomical and physiological 
complexities of modular organs like the liver, the kidney etc., has not been replicated yet and a lot of 
work remains to be done before organ bioengineering will approach the bedside and so change the 
paradigm that has dominated transplant medicine for more than a century using lab-grown organs 
rather than organs procured from deceased or living donors. However, the proof of concept has been 
provided and researchers are now studying how to fully develop its potential and allow translation. 
Despite the road to the ultimate objective appears long, winding and difficult (Figure 2), the different 
RM technologies are still immature and several questions will have to be answered before translation 
may occur (Table 1), the days when success will be the usual outcome are ahead of us and closer are 
the days when TM, a discipline that traditionally has been immunology-based [134, 135], will realize 
that RM should become its major research core. If we agree on this, then TM should allocate more 
funds to RM-inspired research, transplant societies should twin with RM societies and established RM 
community of practices and committees, transplant journals and conferences should grant the due 
consideration and visibility to RM manuscripts. The good news is that most of this is already being 
done.   
To the authors of the present manuscript, it is clear that no field in health sciences has more 
interest than organ transplantation in fostering progress in RM simply because the future of no other 
field more than the future of TM will be determined and forged by progress occurring in RM. 
  
Figure 1.  In the history of organ transplantation, we identify three phases or eras. The first 
can be referred to as the surgery phase and spans from the early days to the advent of 
cyclosporine. The introduction of this potent immunosuppressant allowed transplantation to 
become a lifesaving procedure for a myriad of clinical scenarios characterized by irreversible 
organ failure. The second phase (immunology) spans from the advent of cyclosporine to 
nowadays. During that phase, we have learned how to manage anti-rejection medications and 
their impact on patient’s quality of life. Importantly, given the burden of side effects that 
comes with lifelong immunosuppression, we have realized that we should devise strategies to 
minimize the immunosuppression if not withdrawing it completely sometime after the 
transplant. Unfortunately, immunosuppression-free transplantation remains unrealistic, 
despite intense research and multiple attempts to translate promising laboratory findings into 
the clinic[136, 137]. The third phase has just begun and can be referred to as the regenerative 
medicine phase. RM promises to meet the most urgent needs of modern transplantation, 
namely, the identification of a new potentially inexhaustible source of organs and 
immunosuppression-free transplantation (adapted from Salvatori et al. Xenotransplantation 
2015 and Orlando G. Transplantation 2017, with permission).  
	
 
 
Figure 2. Roadmap for ex vivo solid organ bioengineering using decellularization and 3D 
printing technologies. The figure briefly summarizes the milestones to reach on the path 
towards the Holy Grail. However, the cartoon does not contemplate interspecies blastocyst 
complementation, which – to the authors – bears the greatest potential for the field because 
all steps of organ ontogenesis occur in vivo and are strictly regulated by the surrogate animal, 
without any need for any intervention from the outside. Instead, based on current views, in 
the case of decellularization and 3D printing, cells and supporting scaffolding materials need 
to go through a maturation phase whose duration, dynamic and physiology remain largely 
unknown. 
  
Table 1. State of the art, perspective and hurdles to overcome in the major RM technologies 
of transplant interest.  
 
Legend: ECMs extracellular matrix scaffolds; aECMs acellular ECMs; iPSC induced 
pluripotent stem cells; IBC interspecies blastocyst complementation; GLP good laboratory 
practice 
 
	
	
 State of the art Perspective and hurdles to 
overcome 
DECELLULARIZATION 1. Virtually all organs from 
all clinically relevant 
mammalian species 
including humans can be 
decellularized to obtain 
acellular ECMs 
2. aECMs preserves most yet 
not all molecular and 
physical characteristics of 
the innate ECM, as the 
decellularization process 
damages the ECM to an 
extent that depends on the 
method and the organ 
3. Partial regeneration of the 
endothelial and 
parenchymal 
compartments has been 
reported, yet results are 
inconsistent and difficult 
to reproduce 
4. The maturation phase 
reported in the literature 
for the different organs 
was always far inferior to 
the time needed in utero to 
develop the organs in 
questions 
5. The implantation in vivo 
of a viable and 
functioning bioengineered 
organ has never been 
reported   
1. In-depth understanding 
of the mechanisms 
underlying organ 
development, 
regeneration and 
homeostasis  
2. In-depth understanding 
of the mechanisms of 
ECM-cell interactions 
3. Cell selection for 
recellularization 
4. Harmonious 
harnessing of 
lymphatic, nervous and 
vascular components   
5. Improving the design 
of ad hoc bioreactors 
to support maturation 
6. Strategies to achieve 
adequate 
recellularization  
3D 1. Successful isolation and 
expansion of many 
functional and supportive 
cell types 
2. Replication of mechanical 
and biophysical properties 
1. Production of an 
adequate number of 
regeneration-
competent cells that do 
not elicit an immune 
repose following 
of simple tissues at the 
macro-level 
3. Bioprinting of cells with 
natural and synthetic 
biomaterials with high 
resolution 
4. Implantation and in vivo 
maturation of small 
avascular tissues 
transplantation 
2. ECM-based materials 
that provide much 
stronger mechanical 
strength while 
maintaining the cell-
supportive 
environment 
3. Improvements in 
speed, resolution, 
material flexibility and 
scalability of 
bioprinters 
4. Bioprinting of multi-
scale vascular 
networks within 
instructive bioink that 
promotes angiogenic 
sprouting and 
neovascularization 
 
 iPSCs 1. Generation of various 
types of complex 
organoids in vitro (e.g., 
renal, liver, heart, 
pancreas) from human 
iPSCs 
2. Generation of human 
pancreatic tissue in vivo 
following transplantation 
of iPSC-derived organoids 
in mice 
3. iPSCs can be generated 
from individual patients, 
circumventing the need 
for immunosuppressants 
following transplantation 
into patients 
 
1. iPSC-derived 
organoids typically 
resemble foetal 
tissues/organs and are 
unlikely to mature into 
functioning adult 
organs 
2. iPSC-derived 
organoids generated in 
vitro do not have the 
blood vessels, 
lymphatics and 
neuronal innervation 
required for them to 
function in vivo 
IBC 1. Development of 
functional rat pancreata 
following IBC of Pdx1-/- 
mouse blastocysts 
2. Generation of a biallelic 
knockout in pigs using 
nuclease-based genome 
editing shows it could be 
possible to generate pig 
embryos for IBC that lack 
specific organs 
1. To improve the 
efficiency of 
generating human-pig 
chimeric embryos, we 
need a greater 
understanding of how 
the status of human 
iPSCs (ie, whether 
they are ‘naïve’, 
‘primed’ or 
‘intermediate’) affects 
3. Development of mouse-
human and pig-human  
chimeric embryos using 
‘primed’ human iPSCs  
their ability to 
integrate into post-
implantation pig 
embryos 
2. The contribution of 
human iPSCs to 
developing pig 
embryos is limited and 
it has not yet been 
possible to generate 
human organs using 
IBC 
3. Even if the above 
challenges were 
addressed, a further 
problem is that human 
organs developed 
using IBC would have 
pig blood vessels, 
lymphatics and 
neuronal innervation, 
which would probably 
lead to immune-
rejection. 
RM for IR 1. Multiple candidate cell 
populations showing 
efficacy beyond previous 
small molecule 
alternatives. 
2. Emerging evidence of 
favourable biodistribution 
avoiding off-site effects 
3. Natural organ architecture 
available in transplant 
context. 
4. Complementary benefits 
with normothermic, ex-
vivo perfusion. 
1 Obtaining adequate numbers 
of point of care derived 
autologous cells. 
2. Obtaining adequate 
numbers of efficacious, non-
immunogenic GLP 
manufactured allogeneic cells. 
3.  Reassurance regarding 
potential 
vascular/microvascular 
complications 
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